Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: FAT1

Gene summary for FAT1

Gene summary.

Gene information	Species	Human
	Gene symbol	FAT1
	Gene ID	2195
	Gene name	FAT atypical cadherin 1
	Gene Alias	CDHF7
	Cytomap	4q35.2
	Gene Type	protein-coding
	GO ID	GO:0000902
	UniProtAcc	Q14517

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2195	FAT1	CA_HPV_1	Human	Cervix	CC	5.98e-15	-3.11e-01	0.0264
2195	FAT1	CCI_3	Human	Cervix	CC	1.19e-05	8.23e-01	0.516
2195	FAT1	T1	Human	Cervix	CC	8.35e-04	3.31e-01	0.0918
2195	FAT1	HTA11_3410_2000001011	Human	Colorectum	AD	2.57e-15	-5.42e-01	0.0155
2195	FAT1	HTA11_3361_2000001011	Human	Colorectum	AD	2.35e-03	-5.50e-01	-0.1207
2195	FAT1	HTA11_99999971662_82457	Human	Colorectum	MSS	5.36e-03	5.78e-01	0.3859
2195	FAT1	HTA11_99999974143_84620	Human	Colorectum	MSS	1.39e-03	-3.73e-01	0.3005
2195	FAT1	F007	Human	Colorectum	FAP	1.81e-03	1.49e-01	0.1176
2195	FAT1	A002-C-010	Human	Colorectum	FAP	6.29e-03	3.65e-02	0.242
2195	FAT1	A001-C-207	Human	Colorectum	FAP	1.14e-04	4.28e-02	0.1278
2195	FAT1	A015-C-203	Human	Colorectum	FAP	1.38e-32	-4.57e-02	-0.1294
2195	FAT1	A015-C-204	Human	Colorectum	FAP	1.72e-06	-1.83e-01	-0.0228
2195	FAT1	A014-C-040	Human	Colorectum	FAP	1.94e-05	-7.64e-02	-0.1184
2195	FAT1	A002-C-201	Human	Colorectum	FAP	5.22e-16	-3.65e-02	0.0324
2195	FAT1	A002-C-203	Human	Colorectum	FAP	1.89e-02	-2.00e-02	0.2786
2195	FAT1	A001-C-119	Human	Colorectum	FAP	3.69e-07	-2.78e-02	-0.1557
2195	FAT1	A001-C-108	Human	Colorectum	FAP	5.20e-20	2.08e-01	-0.0272
2195	FAT1	A002-C-021	Human	Colorectum	FAP	3.10e-02	3.32e-01	0.1171
2195	FAT1	A002-C-205	Human	Colorectum	FAP	4.87e-33	2.56e-01	-0.1236
2195	FAT1	A001-C-104	Human	Colorectum	FAP	2.64e-07	2.02e-01	0.0184

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000701510	Cervix	CC	actin filament organization	109/2311	442/18723	4.92e-13	2.45e-10	109
GO:00071639	Cervix	CC	establishment or maintenance of cell polarity	63/2311	218/18723	4.25e-11	8.76e-09	63
GO:00300108	Cervix	CC	establishment of cell polarity	42/2311	143/18723	4.30e-08	2.62e-06	42
GO:000206410	Cervix	CC	epithelial cell development	45/2311	220/18723	4.14e-04	4.21e-03	45
GO:00901627	Cervix	CC	establishment of epithelial cell polarity	11/2311	31/18723	7.87e-04	6.96e-03	11
GO:00017384	Cervix	CC	morphogenesis of a polarized epithelium	22/2311	94/18723	2.09e-03	1.52e-02	22
GO:0150063	Cervix	CC	visual system development	63/2311	375/18723	6.58e-03	3.65e-02	63
GO:0001654	Cervix	CC	eye development	62/2311	371/18723	7.83e-03	4.13e-02	62
GO:0048880	Cervix	CC	sensory system development	63/2311	381/18723	9.29e-03	4.66e-02	63
GO:0007015	Colorectum	AD	actin filament organization	167/3918	442/18723	1.65e-16	7.94e-14	167
GO:0002064	Colorectum	AD	epithelial cell development	89/3918	220/18723	2.98e-11	3.52e-09	89
GO:0007163	Colorectum	AD	establishment or maintenance of cell polarity	77/3918	218/18723	5.72e-07	2.08e-05	77
GO:0030010	Colorectum	AD	establishment of cell polarity	50/3918	143/18723	6.90e-05	1.11e-03	50
GO:0045197	Colorectum	AD	establishment or maintenance of epithelial cell apical/basal polarity	20/3918	44/18723	2.26e-04	2.94e-03	20
GO:0035088	Colorectum	AD	establishment or maintenance of apical/basal cell polarity	21/3918	49/18723	4.31e-04	4.82e-03	21
GO:0061245	Colorectum	AD	establishment or maintenance of bipolar cell polarity	21/3918	49/18723	4.31e-04	4.82e-03	21
GO:0001738	Colorectum	AD	morphogenesis of a polarized epithelium	31/3918	94/18723	4.30e-03	2.95e-02	31
GO:0030859	Colorectum	AD	polarized epithelial cell differentiation	11/3918	24/18723	5.43e-03	3.55e-02	11
GO:0090162	Colorectum	AD	establishment of epithelial cell polarity	13/3918	31/18723	6.53e-03	4.06e-02	13
GO:00070152	Colorectum	MSS	actin filament organization	146/3467	442/18723	1.16e-13	2.67e-11	146

Page: 1 2 3 4 5 6 7 8 9 10

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

FAT1

SNV

Missense_Mutation

c.7117N>A

p.Asp2373Asn

p.D2373N

Q14517

protein_coding

deleterious(0)

possibly_damaging(0.715)

TCGA-A2-A0CX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

FAT1

SNV

Missense_Mutation

c.3131A>G

p.Lys1044Arg

p.K1044R

Q14517

protein_coding

tolerated(0.15)

benign(0.052)

TCGA-A2-A0D0-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

FAT1

SNV

Missense_Mutation

c.6226G>A

p.Asp2076Asn

p.D2076N

Q14517

protein_coding

deleterious(0)

probably_damaging(0.998)

TCGA-A7-A0CE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

FAT1

SNV

Missense_Mutation

rs200357548

c.10478N>T

p.Pro3493Leu

p.P3493L

Q14517

protein_coding

deleterious(0.02)

benign(0.081)

TCGA-A8-A08T-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

FAT1

SNV

Missense_Mutation

novel

c.404T>C

p.Val135Ala

p.V135A

Q14517

protein_coding

deleterious(0)

benign(0.345)

TCGA-A8-A09Z-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

FAT1

SNV

Missense_Mutation

c.6179N>T

p.Ser2060Phe

p.S2060F

Q14517

protein_coding

tolerated(0.57)

possibly_damaging(0.748)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

FAT1

SNV

Missense_Mutation

novel

c.6445G>A

p.Glu2149Lys

p.E2149K

Q14517

protein_coding

deleterious(0.03)

benign(0.243)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

FAT1

SNV

Missense_Mutation

rs772458580

c.1654G>A

p.Glu552Lys

p.E552K

Q14517

protein_coding

deleterious(0.02)

possibly_damaging(0.685)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

FAT1

SNV

Missense_Mutation

c.9619N>G

p.Pro3207Ala

p.P3207A

Q14517

protein_coding

tolerated(0.06)

probably_damaging(0.999)

TCGA-AN-A0FV-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

FAT1

SNV

Missense_Mutation

rs371394820

c.5284N>A

p.Ala1762Thr

p.A1762T

Q14517

protein_coding

tolerated(0.22)

benign(0.022)

TCGA-AQ-A1H2-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

herceptin

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1